Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK GABRIEL LEBWOHL

Allopathic & Osteopathic Physicians Dermatology

NPI
1013902444
CMS profile
137094
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$162,308.75

299 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 299 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK GABRIEL LEBWOHL

NPI 1013902444 · CMS profile ID 137094

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 299 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013902444?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK GABRIEL LEBWOHL, NPI 1013902444, CMS profile ID 137094. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 299 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013902444?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARK GABRIEL LEBWOHL, NPI 1013902444, CMS profile ID 137094. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 299 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013902444?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARK GABRIEL LEBWOHL, NPI 1013902444, CMS profile ID 137094, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 299 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1013902444?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

299 matching records · $162,308.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 299 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 299.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $2,266.5004/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087137934 CMS
Novartis Pharmaceuticals Corporation $625.0504/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087137958 CMS
Novartis Pharmaceuticals Corporation $16.1004/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087137960 CMS
Genentech USA, Inc. $35.7304/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062650 CMS
Genentech USA, Inc. $281.9104/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062655 CMS
Genentech USA, Inc. $11.5804/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062659 CMS
Genentech USA, Inc. $8,695.0004/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062663 CMS
Genentech USA, Inc. $353.1404/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062667 CMS
Genentech, Inc. $130.6204/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062671 CMS
Boehringer Ingelheim International GmbH $926.8303/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838042 CMS
Boehringer Ingelheim International GmbH $1,208.7203/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838052 CMS
Boehringer Ingelheim International GmbH $1,538.3703/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838056 CMS
Boehringer Ingelheim International GmbH $477.9303/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838184 CMS
Boehringer Ingelheim International GmbH $505.5503/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838188 CMS
Boehringer Ingelheim International GmbH $505.5503/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838190 CMS
Incyte Corporation $9,000.0003/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267793 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $556.1003/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838030 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,112.2003/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117838048 CMS
E.R. Squibb & Sons, L.L.C. $13.3903/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262339 CMS
E.R. Squibb & Sons, L.L.C. $8.4003/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262341 CMS
E.R. Squibb & Sons, L.L.C. $17.5303/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262343 CMS
Janssen Biotech, Inc. $6.8203/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078448006 CMS
Janssen Biotech, Inc. $14.2403/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454472 CMS
E.R. Squibb & Sons, L.L.C. $8.4003/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262337 CMS
Janssen Biotech, Inc. $6.8203/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078444330 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $100.2203/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152178620 CMS
Galderma Laboratories, L.P. $5.3103/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311856 CMS
PFIZER INC. $106.7403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131613398 CMS
E.R. Squibb & Sons, L.L.C. $41.4403/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262335 CMS
Janssen Biotech, Inc. $16.7103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078441541 CMS
Janssen Biotech, Inc. $15.5203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078450178 CMS
Janssen Biotech, Inc. $26.1303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078456071 CMS
Janssen Biotech, Inc. $394.5203/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078445772 CMS
Takeda Pharmaceuticals U.S.A., Inc. $113.0003/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137615638 CMS
Janssen Biotech, Inc. $10.8703/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078449651 CMS
Janssen Biotech, Inc. $33.6503/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078457130 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.3503/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913114 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $147.3703/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913116 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $59.4103/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913118 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.0403/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913120 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $12.1803/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1154913122 CMS
Lilly USA, LLC $5.7502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135167204 CMS
Eli Lilly and Company $34.0602/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135156845 CMS
Eli Lilly and Company $19.0702/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135156847 CMS
Incyte Corporation $79.0302/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141316551 CMS
E.R. Squibb & Sons, L.L.C. $48.3702/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101262365 CMS
UCB, Inc. $32.2502/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143257461 CMS
UCB, Inc. $45.0202/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143257465 CMS
LEO Pharma Inc. $35.4302/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152639551 CMS
Novartis Pharmaceuticals Corporation $73.8102/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087137918 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $72,097.45 170
PY2020 $60,770.88 55
PY2021 $84,627.07 105
PY2022 $110,548.66 151
PY2023 $114,458.17 183
PY2024 $162,308.75 299
PY2025 $127,834.06 181

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $26,299.68 9
PY2025 Principal investigator $486,926.56 26
PY2024 Recipient $10,548.76 10
PY2024 Principal investigator $402,509.78 23
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $270,076.13 29
PY2022 Recipient $35,810.00 10
PY2022 Principal investigator $838,274.25 66
PY2021 Recipient $88,113.90 53
PY2021 Principal investigator $950,924.43 79
PY2020 Recipient $34,319.58 29
PY2020 Principal investigator $586,539.85 45
PY2019 Recipient $51,239.24 15
PY2019 Principal investigator $1,487,788.22 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $12,490.00 12/25/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175314675
Principal investigator 1 Janssen Research & Development, LLC $2,777.00 12/25/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315083
Recipient Novartis Pharmaceuticals Corporation $1,954.96 12/12/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292980
Principal investigator 1 Janssen Research & Development, LLC $7,776.00 12/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314531
Principal investigator 1 Janssen Research & Development, LLC $425.00 11/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314451
Principal investigator 1 Janssen Research & Development, LLC $425.00 11/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314961
Principal investigator 1 Janssen Research & Development, LLC $425.00 11/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315115
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/03/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175315068
Principal investigator 1 Janssen Research & Development, LLC $5,184.00 10/31/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314908
Recipient Boehringer Ingelheim International GmbH $4,068.75 10/30/2025 Covered Recipient Physician A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220623684
Principal investigator 1 Janssen Research & Development, LLC $7,497.00 10/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175314859
Principal investigator 1 Boehringer Ingelheim International GmbH $7,440.40 09/30/2025 Non-covered Recipient Entity
Mt Sinai School Of Medicine Department Of Ophthalmology
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220641041
Principal investigator 1 Janssen Research & Development, LLC $2,156.00 09/29/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314311
Principal investigator 1 Janssen Research & Development, LLC $7,497.00 09/29/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175314666
Recipient Amgen Inc. $111.70 09/23/2025 Covered Recipient Physician A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects with Palmoplantar Pustulosis (PPP) No dispute reported 06/30/2026 1246636806
Recipient Amgen Inc. $4,242.99 09/23/2025 Covered Recipient Physician A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1246636808
Principal investigator 1 Janssen Research & Development, LLC $14,856.00 09/08/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175315478
Principal investigator 1 Janssen Research & Development, LLC $5,457.00 09/04/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314299
Principal investigator 1 Janssen Research & Development, LLC $21,186.00 07/31/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175315470
Principal investigator 1 Janssen Research & Development, LLC $3,638.00 07/28/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315445
Recipient Boehringer Ingelheim International GmbH $4,650.00 07/14/2025 Covered Recipient Physician A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220623682
Principal investigator 1 Janssen Research & Development, LLC $27,439.00 07/07/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175314357
Principal investigator 1 Janssen Research & Development, LLC $6,416.00 06/26/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314437
Recipient Boehringer Ingelheim International GmbH $2,712.50 05/22/2025 Covered Recipient Physician A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220623680
Principal investigator 1 Janssen Research & Development, LLC $12,412.00 05/22/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175314591
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 04/28/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226140732
Principal investigator 1 Janssen Research & Development, LLC $4,074.00 03/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315602
Recipient Novartis Pharma AG $4,337.00 03/20/2025 Covered Recipient Physician CLOU064A2301,CLOU064A2302 No dispute reported 06/30/2026 1248109395
Recipient Eli Lilly and Company $82.31 03/03/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187871197
Principal investigator 1 Janssen Research & Development, LLC $21,564.00 03/03/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315294
Principal investigator 1 Eli Lilly and Company $274,490.00 02/18/2025 Non-covered Recipient Entity
MOUNT SINAI SCHOOL OF MEDICINE
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187886594
Principal investigator 1 ABBVIE INC. $26,542.50 02/12/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 1202450567
Principal investigator 1 Janssen Research & Development, LLC $6,699.00 01/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175315017
Principal investigator 1 Eli Lilly and Company $5,610.66 01/16/2025 Non-covered Recipient Entity
MOUNT SINAI SCHOOL OF MEDICINE
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187885894
Recipient Novartis Pharmaceuticals Corporation $4,139.47 01/10/2025 Covered Recipient Physician CLOU064A2301,CLOU064A2302 No dispute reported 06/30/2026 1190292737